medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2016, Número 6

<< Anterior Siguiente >>

Ann Hepatol 2016; 15 (6)


PARK2 polymorphisms predict disease progression in patients infected with hepatitis C virus

Al-Qahtani AA, Al-Anazi MR, Al-Zoghaibi FA, Abdo AA, Sanai FM, Al-Hamoudi WK, Alswat KA, Al-Ashgar HI, Khan MQ, Albenmousa A, Khalak H, Al-Ahdal MN

Idioma: Ingles.
Referencias bibliográficas: 54
Paginas: 824-833
Archivo PDF: 172.70 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Chisari FV. Unscrambling hepatitis C virus-host interactions. Nature 2005; 436: 930-2.

  2. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 2014; 61: S58-S68.

  3. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009; 10: 704-14.

  4. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: S35-S46.

  5. Lin MV, King LY, Chung RT. Hepatitis C virus-associated cancer. Annu Rev Pathol 2015; 10: 345-70.

  6. Yamashita T, Honda M, Kaneko S. Molecular mechanisms of hepatocarcinogenesis in chronic hepatitis C virus infection. J Gastroenterol Hepatol 2011; 26: 960-4.

  7. Jeong SW, Jang JY, Chung RT. Hepatitis C virus and hepatocarcinogenesis. Clin Mol Hepatol 2012; 18: 347-56.

  8. Mikula M, Proell V, Fischer AN, Mikulits W. Activated hepatic stellate cells induce tumor progression of neoplastic hepatocytes in a TGF-beta dependent fashion. J Cell Physiol 2006; 209: 560-7.

  9. Park YN, Yang CP, Cubukcu O, Thung SN, Theise ND. Hepatic stellate cell activation in dysplastic nodules: evidence for an alternate hypothesis concerning human hepatocarcinogenesis. Liver 1997; 17: 271-4.

  10. Tsai WL, Chung RT. Viral hepatocarcinogenesis. Oncogene 2010; 29: 2309-24.

  11. Hohler T, Kruger A, Gerken G, Schneider PM, Meyer zum Buschenfelde KH, Rittner C. Tumor necrosis factor alpha promoter polymorphism at position -238 is associated with chronic active hepatitis C infection. J Med Virol 1998; 54: 173-7.

  12. Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DH, Shorthouse C, Purdie DM, et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000; 31: 828-33.

  13. Harris RA, Sugimoto K, Kaplan DE, Ikeda F, Kamoun M, Chang KM. Human leukocyte antigen class II associations with hepatitis C virus clearance and virus-specific CD4 T cell response among Caucasians and African Americans. Hepatology 2008; 48: 70-9.

  14. McKiernan SM, Hagan R, Curry M, McDonald GS, Kelly A, Nolan N, Walsh A, et al. Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source. Hepatology 2004; 40: 108-14.

  15. Neumann-Haefelin C, McKiernan S, Ward S, Viazov S, Spangenberg HC, Killinger T, Baumert TF, et al. Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution. Hepatology 2006; 43: 563-72.

  16. Sun H, Pan Y, Wu R, Lv J, Chi X, Wang X, Tu Z, et al. CD24 Ala57Val polymorphism is associated with spontaneous viral clearance in the HCV-infected Chinese population. Liver Int 2015; 35: 786-94.

  17. Labib HA, Ahmed HS, Shalaby SM, Wahab EA, Hamed EF. Genetic polymorphism of IL-23R influences susceptibility to HCV-related hepatocellular carcinoma. Cell Immunol 2015; 294: 21-4.

  18. Wei Y, Liu F, Li B, Chen X, Ma Y, Yan L, Wen T, et al. Polymorphisms of tumor necrosis factor-alpha and hepatocellular carcinoma risk: a HuGE systematic review and meta-analysis. Dig Dis Sci 2011; 56: 2227-36.

  19. Al-Anazi MR, Matou-Nasri S, Abdo AA, Sanai FM, Khan MQ, Albenmousa A, Al-Ashgar, et al. Variations in DEPDC5 gene and its association with chronic hepatitis C virus infection in Saudi Arabia. BMC Infect Dis 2014; 14: 3839.

  20. Mangia A, Santoro R, Piattelli M, Pazienza V, Grifa G, Iacobellis A, Andriulli A. IL-10 haplotypes as possible predictors of spontaneous clearance of HCV infection. Cytokine 2004; 25: 103-9.

  21. Nischalke HD, Berger C, Luda C, Müller T, Berg T, Coenen M, Krämer B, et al. The CXCL1 rs4074 A allele is associated with enhanced CXCL1 responses to TLR2 ligands and predisposes to cirrhosis in HCV genotype 1-infected Caucasian patients. J Hepatol 2012; 56: 758-64.

  22. Wasmuth HE, Zaldivar MM, Berres ML, Werth A, Scholten D, Hillebrandt S, Tacke F, et al. The fractalkine receptor CX3CR1 is involved in liver fibrosis due to chronic hepatitis C infection. J Hepatol 2008; 48: 208-15.

  23. Asakawa S, Tsunematsu K, Takayanagi A, Sasaki T, Shimizu A, Shintani A, Kawasaki K, et al. The genomic structure and promoter region of the human parkin gene. Biochem Biophys Res Commun 2001; 286: 863-8.

  24. Beasley SA, Hristova VA, Shaw GS. Structure of the Parkin in-between-ring domain provides insights for E3-ligase dysfunction in autosomal recessive Parkinson’s disease. Proc Natl Acad Sci U S A 2007; 104: 3095-100.

  25. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392: 605-8.

  26. Chopra R, Ali S, Srivastava AK, Aggarwal S, Kumar B, Manvati S, Kalaiarasan P, et al. Mapping of PARK2 and PACRG overlapping regulatory region reveals LD structure and functional variants in association with leprosy in unrelated indian population groups. PLoS Genet 2013; 9: e1003578.

  27. Malhotra D, Darvishi K, Lohra M, Kumar H, Grover C, Sood S, Reddy BS, et al. Association study of major risk single nucleotide polymorphisms in the common regulatory region of PARK2 and PACRG genes with leprosy in an Indian population. Eur J Hum Genet 2006; 14: 438-42.

  28. Mira MT, Alcais A, Nguyen VT, Moraes MO, Di Flumeri C, Vu HT, Mai CP, et al. Susceptibility to leprosy is associated with PARK2 and PACRG. Nature 2004; 427: 636-40.

  29. Glessner JT, Wang K, Cai G, Korvatska O, Kim CE, Wood S, Zhang H, et al. Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature 2009; 459: 569-73.

  30. Wongseree W, Assawamakin A, Piroonratana T, Sinsomros S, Limwongse C, Chaiyaratana N. Detecting purely epistatic multi-locus interactions by an omnibus permutation test on ensembles of two-locus analyses. BMC Bioinformatics 2009; 10: 294.

  31. Burns MP, Zhang L, Rebeck GW, Querfurth HW, Moussa CE. Parkin promotes intracellular Abeta1-42 clearance. Hum Mol Genet 2009; 18: 3206-16.

  32. Cesari R, Martin ES, Calin GA, Pentimalli F, Bichi R, McAdams H, Trapasso F, et al. Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc Natl Acad Sci U S A 2003; 100: 5956-61.

  33. Veeriah S, Taylor BS, Meng S, Fang F, Yilmaz E, Vivanco I, Janakiraman M, et al. Somatic mutations of the Parkinson’s disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet 2010; 42: 77-82.

  34. Chaudhary S, Behari M, Dihana M, Swaminath PV, Govindappa ST, Jayaram S, Goyal V, et al. Parkin mutations in familial and sporadic Parkinson’s disease among Indians. Parkinsonism Relat Disord 2006; 12: 239-45.

  35. Bonder A, Afdhal N. Utilization of FibroScan in clinical practice. Curr Gastroenterol Rep 2014; 16: 372.

  36. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.

  37. Calvaruso V, Craxí A. 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver International 2012; 32: 2-8.

  38. Abdo AA, Sanai FM, Al-Faleh FZ. Epidemiology of viral hepatitis in Saudi Arabia: are we off the hook? Saudi J Gastroenterol 2012; 18: 349-57.

  39. Abozaid SM, Shoukri M, Al-Qahtani A, Al-Ahdal MN. Prevailing genotypes of hepatitis C virus in Saudi Arabia: a systematic analysis of evidence. Ann Saudi Med 2013; 33: 1-5.

  40. WHO: World Health Organization Regional Committee for the Eastern Mediterranean; The growing threats of hepatitis B and C in the Eastern Mediterranean Region: A call for action. 2009. Available from: http://applications.emro.who.int/docs/ EM_RC56_3_en.pdf

  41. Li K, Lemon SM. Innate immune responses in hepatitis C virus infection. Semin Immunopathol 2013; 35: 53-72.

  42. Chuang WL, Yu ML. Host factors determining the efficacy of hepatitis C treatment. J Gastroenterol 2013; 48: 22-30.

  43. Slev P. Host genomics and HCV personalized medicine. Ann Clin Lab Sci 2012; 42: 363-9.

  44. Gao L, Tu H, Shi ST, Lee KJ, Asanaka M, Hwang SB, Lai MM. Interaction with a ubiquitin-like protein enhances the ubiquitination and degradation of hepatitis C virus RNA-dependent RNA polymerase. J Virol 2003; 77: 4149-59.

  45. Hou W, Tian Q, Zheng J, Bonkovsky HL. Zinc mesoporphyrin induces rapid proteasomal degradation of hepatitis C nonstructural 5A protein in human hepatoma cells. Gastroenterology 2010; 138: 1909-19.

  46. Zhang S, Sha Q, Chen HS, Dong J, Jiang R. Transmission/ disequilibrium test based on haplotype sharing for tightly linked markers. Am J Hum Genet 2003; 73: 566-79.

  47. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.

  48. Rao HY, Sun DG, Jiang D, Yang RF, Guo F, Wang JH, Liu F, et al. IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection. J Viral Hepat 2012; 19: 173-81.

  49. Tillmann HL, Thompson AJ, Patel K, Wiese M, Tenckhoff H, Nischalke HD, Lokhnygina Y, et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010; 139: 1586-92, 1592 e1.

  50. Wang JH, Zheng X, Ke X, Dorak MT, Shen J, Boodram B, O’Gorman M, et al. Ethnic and geographical differences in HLA associations with the outcome of hepatitis C virus infection. Virol J 2009; 6: 46.

  51. Thio CL, Gao X, Goedert JJ, Vlahov D, Nelson KE, Hilgartner MW, O’Brien SJ, et al. HLA-Cw*04 and hepatitis C virus persistence. J Virol 2002; 76: 4792-7.

  52. Ali S, Vollaard AM, Widjaja S, Surjadi C, van de Vosse E, van Dissel JT. PARK2/PACRG polymorphisms and susceptibility to typhoid and paratyphoid fever. Clin Exp Immunol 2006; 144: 425-31.

  53. Houde M, Bertholet S, Gagnon E, Brunet S, Goyette G, Laplante A, Princiotta MF, et al. Phagosomes are competent organelles for antigen cross-presentation. Nature 2003; 425: 402-6.

  54. Kubori T, Galan JE. Temporal regulation of salmonella virulence effector function by proteasome-dependent protein degradation. Cell 2003; 115: 333-42.




2020     |     www.medigraphic.com